Kalvista Pharmaceuticals Inc Asset Resilience Ratio
Kalvista Pharmaceuticals Inc asset resilience ratio. Kalvista Pharmaceuticals Inc (KALV) has an Asset Resilience Ratio of 19.32% as of October 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Kalvista Pharmaceuticals Inc (KALV) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Kalvista Pharmaceuticals Inc (2015–2025)
Asset resilience ratio of Kalvista Pharmaceuticals Inc from 2015 to 2025. This chart shows how Kalvista Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read Kalvista Pharmaceuticals Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Kalvista Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see KALV asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $65.66 Million | 19.32% |
| Total Liquid Assets | $65.66 Million | 19.32% |
Asset Resilience Insights
- Good Liquidity Position: Kalvista Pharmaceuticals Inc maintains a healthy 19.32% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Kalvista Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Kalvista Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Kalvista Pharmaceuticals Inc Asset Resilience Ratio by Year (2015–2025)
Kalvista Pharmaceuticals Inc asset resilience ratio by year from 2015 to 2025. The table below shows the annual Asset Resilience Ratio data for Kalvista Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-04-30 | 35.49% | $89.00 Million | $250.77 Million | -40.38pp |
| 2024-04-30 | 75.87% | $178.61 Million | $235.40 Million | +25.04pp |
| 2023-04-30 | 50.84% | $93.14 Million | $183.20 Million | -15.61pp |
| 2022-04-30 | 66.45% | $135.47 Million | $203.88 Million | -6.47pp |
| 2021-04-30 | 72.91% | $198.34 Million | $272.01 Million | +16.80pp |
| 2020-04-30 | 56.12% | $51.92 Million | $92.53 Million | -2.13pp |
| 2019-04-30 | 58.24% | $68.81 Million | $118.13 Million | -- |
| 2018-04-30 | 0.00% | $0.00 | $61.39 Million | -- |
| 2017-04-30 | 0.00% | $0.00 | $34.34 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $56.79 Million | -- |
About Kalvista Pharmaceuticals Inc
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which … Read more